The National Lung Screening Trial (NLST) conducted by the U.S. National Cancer Institute found a significant 20% reduction in lung cancer mortality, after three annual LDCT screens.
Although the NLST results are encouraging, more investigation is needed in the areas of: over-diagnosis; net benefit versus harm; at risk population to screen; frequency and duration of LDCT screening; the most appropriate diagnostic work-up of screen detected abnormalities; and implications for public policy.
Results from the expert panel
|Lung cancer screening expert panel: summary of existing and new evidence
The purpose of this document is to review the current evidence regarding lung cancer screening using low dose computed tomography, to assist health professionals and policy-makers in making an informed decision on lung cancer screening in Canada. Released: September 22, 2011